Ageing diseases

The next step was to augment and expand the model to be able to predict the dose response for the comparator. Comparator data, from SBA (summary basis for approval data submitted to the FDA), yielded one model that predicted both candidate and comparator performance. The model accounted for age, disease baseline, and trial differences. Differences based on sex, weight, and other covariates were estimated to be negligible. The addition of the comparator data improved the predictive ability of the model for both drugs (Fig. 22.3). 

Other patient variables may affect GI motility and, thereby, the extent or rate of availability of a drug from a delivery system. As illustrated in Chapter 2, the degree of physical activity, age, disease state, and emotional condition of a patient may increase or de-... 

Electrolyte requirements depend on the patient s age, disease state, organ function, drug therapy, nutrition status, and extrarenal losses. 

Glutamine synthetase, a brain Mn enzyme, is located mainly in astrocytes, and its synthesis may be modulated by nitric oxide (496). Inhibition of this enzyme could be relevant to aging diseases (497). There is evidence that human NT2-N neurons die via ionotropic glutamate receptor-mediated mechanisms when exposed to hypoxia in the presence of glutamate (498). 

We are living in an aging society. The United Nations estimates that the world will have two billion people over the age of 60 by 2050. With the aging population, there are old age diseases that we have to face and treat with more effective therapies. Hypertension, stroke, Alzheimer s disease, heart disease, type II diabetes, Parkinson s disease, and osteoporosis are some examples (Exhibit 11.8). 

When considering the Hkely pharmacokinetic profile of a novel compound in man, it is important to recognize the variability that may be encountered in the cHnical setting. Animal pharmacokinetic studies are generally conducted in inbred animal colonies that tend to show minimal inter-subject variabiHty. The human population contains a diverse genetic mix, without the additional variability introduced by age, disease states, environmental factors and co-medications. Hence any estimate of pharmacokinetic behaviour in man must be tempered by the expected inherent variability. For compounds with high metabolic clearance (e. g. midazolam), inter-individual variability in metabolic clearance can lead to greater than 10-fold variation in oral clearance and hence systemic exposure [1]. 

PRION PLAQUE EORMATION PROTEIN OXIDATION (In Aging Disease) PROTEIN PRENYLTRANSFERASES... 

Define objectives of treatment before initiation of a drug Note frequency and severity for a drug Dependant on age, disease, and individual patient factors Include drug action, absorption, elimination, and protein binding Are they clinically significant ... 

Marked inter-patient variability exists in the pharmacokinetics of intravenous anaesthetics. Factors that can influence drug disposition include the degree of protein binding, the efficiency of the hepatic and renal clearance systems, physiological changes with ageing, disease states, site of operation, body temperature, and drug interactions (premedicants, volatile anaesthetics). 

Gray A, Feldman HA, McKinlay JB, Longcope C (1991) Age, disease, and changing sex hormone levels in middle-aged men Results of the Massachusetts male aging study. J Clin Endocrinol Metab, 73 1016-1025. 

Adverse effect Lactic acidosis due to biguanides Dose-relation toxic effect Time-course time-independent Susceptibility factors genetic (slow phenformin metabolizers) age disease (impaired liver, kidney, or cardiac function, alcoholism)... 

Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB. 2008. Curcumin and cancer An old-age disease with an age-old solution. Cancer Lett 267 133-164. 

Berlett BS, Stadtman ER. 1997. Protein oxidation in aging, disease, and oxidative stress. J Biol Chem 272 20313-20316. 

In addition, the entry of calcium ions into neurons may sometimes become excessive as a result of aging, disease, or stroke and may initiate some harmful processes that may contribute to the removal of synapses or even the death of neurons. This information tells us quite a lot about the role of glutamate when it works correctly, memories can be formed when it does not work correctly, as when it induces too much calcium to enter the neuron, then death and destruction follow and memory is lost. Thus, maintaining a good balance of function related to the entry of calcium ions is a challenging but critical requirement for neurons, and the amino acid neurotransmitter glutamate plays a critical role in this process. 

Duffy PH, Leakey JE, Pipkin JL, Turturro A, Hart RW. The physiologic, neurologic, and behavioral effects of caloric restriction related to aging, disease, and environmental factors. Environ Res 1997 73 242-248. 

Beal, M. F. (2004). Therapeutic effects of coenzyme Q10 in diseases. Methods Eneymol. 382, 473-487. Beal, M. F., and Matthews, R. T. (1997). Coenzyme Q10 in the central nervous system and its potential usefulness in the treatment ofneurodegenerative diseases. Mol. Aspects Med. 18(Suppl.), 169-179. Berlett, B. S., and Stadtman, E. R. (1997). Protein oxidation in aging, disease, and oxidative stress. 

Influence of host environment of human recipient (age, disease, medical history)... 

An analysis of responses in subsets of the overall population is required. The extent of this part of the integrated summary of efficacy will depend to a large extent on the drug and its intended patient population. Subsets of interest may include sex, race, age, disease severity, concomitant illness, concomitant drugs, smoking and alcoholism, and prior therapy. 

There was a significantly higher risk of late cognitive impairment (concentration and memory) in patients (n = 39) taking adjuvant cyclophosphamide, fluorouracil, and methotrexate than in controls matched for age, disease, surgery, and radiation dose (526). 

Schentag JJ, Cerra FB, Calleri GM, Leising ME, French MA, Bernhard H. Age, disease, and cimeti-dine disposition in healthy subjects and chronically ill patients. Clin Pharmacol Ther 1981 29 737-43. 

B. S. Berlett, E. R. Stadtman, Protein Oxidation in Aging, Disease, and Oxidative Stress, J Biol Chem 111 1991) 20313-6. 

---